FDA approves pralsetinib for lung cancer with RET gene fusions

On September 4, 2020, the Food and Drug Administration granted accelerated approval to pralsetinib (GAVRETOTM, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

Source: FDA Center for Drug Evaluation and Research - What's New - September 8, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news